Greg Hapgood

EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity

Maher K. Gandhi, Thanh Hoang, Soi Cheng Law et al. · Blood · 2020 · 119 citations · Full text

Medicine, Immunology, Oncology +12

The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples

Jenny Butler, Erica Malan, Sanjeev Chunilal et al. · Thrombosis and Haemostasis · 2013 · 83 citations

Medicine, Hematology, Pharmacology +17

Evaluation of the Risk of Relapse in Classical Hodgkin Lymphoma at Event-Free Survival Time Points and Survival Comparison With the General Population in British Columbia

Greg Hapgood, Yvonne Zheng, Laurie H. Sehn et al. · Journal of Clinical Oncology · 2016 · 82 citations

Medicine, Biostatistics, Oncology +15

Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma

Piers Blombery, Ella R. Thompson, Georgina L. Ryland et al. · Oncotarget · 2018 · 73 citations · Full text

Medicine, Molecular Genetics, Oncology +17

High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma

Katharine L. Lewis, Lasse Hjort Jakobsen, Diego Villa et al. · Journal of Clinical Oncology · 2023 · 47 citations · Full text

Medicine, Oncology, Pharmacotherapy +16